Concerta v léčbě hyperkinetické poruchy
| Title in English | Concerta in the treatment hyperkinetic disorder/ADHD in children and adolescents |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Psychiatrie pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | methylphenidate; OROS system; Concerta; ADHD |
| Description | CONCERTA is a once-daily, long-acting formulation of methylphenidate and indicated for the treatment of ADHD in children from six years and adolescents. The osmotic release oral system (OROS) methylphenidate formulation is designed to deliver methylphenidate in a controlled manner for approximately 12 hours, thereby allowing extended coverage of symptoms ADHD during the day. Compared to methylphenidate IR the new OROS formulation of methylphenidate brings numerous benefits: simple dosage improves adherence to treatment, reduces risks of stigmatization and misuse and the stability of serum levels of the medication contributes to a more pronounced effect on neurocognitive and behavioral symptoms of ADHD and improves tolerability and compliance. |